alcohol condition

Phase 1Small molecule

alcohol condition is one of 2 small molecule programs targeting Temporomandibular Disorder (TMD). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Temporomandibular Disorder (TMD)Recruiting

Temporomandibular Disorder (TMD)Phase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Temporomandibular Disorder (TMD)

#DrugCompanyPhaseTrials

alcohol condition

UUniversity of Minnesota

Phase 1

1 2

Ethinyl Estradiol and Levonorgestrel

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 1Recruiting

Temporomandibular Disorder (TMD)

NCT06659991

Clinical

Trials by Indication[1]

Temporomandibular Disorder (TMD)1 trial

JIT: Effects of Pain on Laboratory Drinking Topography and Daily Drinking in People With Chronic Temporomandibular Disorder (TMD) Pain

Recruiting·UUniversity of Minnesota·Phase 1·NCT06659991·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for alcohol condition. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — alcohol condition compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for alcohol condition. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Minnesota company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Minnesota

alcohol condition

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Temporomandibular Disorder (TMD)1 trial

References

Drug Info

Quick Facts

Related News